Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions
PCVX Stock Forecast
Vaxcyte stock forecast is as follows: an average price target of $148.80 (represents a 73.19% upside from PCVX’s last price of $85.92) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
PCVX Price Target
The average price target for Vaxcyte (PCVX) is $148.80 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $163.00 to $135.00. This represents a potential 73.19% upside from PCVX's last price of $85.92.
PCVX Analyst Ratings
According to 9 Wall Street analysts, Vaxcyte's rating consensus is 'Buy'. The analyst rating breakdown for PCVX stock is 0 'Strong Buy' (0.00%), 9 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vaxcyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 06, 2024 | Roger Song | Jefferies | $146.00 | $106.73 | 36.79% | 69.94% |
| Nov 06, 2024 | David Risinger | Leerink Partners | $135.00 | $106.73 | 26.48% | 57.13% |
| Sep 10, 2024 | Salim Syed | Mizuho Securities | $163.00 | $115.28 | 41.39% | 89.72% |
| Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $140.00 | $110.15 | 27.10% | 62.95% |
| Sep 03, 2024 | David Risinger | Leerink Partners | $153.00 | $112.04 | 36.56% | 78.08% |
| Sep 03, 2024 | Tom Shrader | BTIG | $160.00 | $110.15 | 45.26% | 86.23% |
| Sep 03, 2024 | Roger Song | Jefferies | $129.00 | $111.13 | 16.09% | 50.15% |
| Sep 03, 2024 | Salim Syed | Mizuho Securities | $113.00 | $111.08 | 1.72% | 31.53% |
| Aug 07, 2024 | Tom Shrader | BTIG | $98.00 | $70.52 | 38.97% | 14.07% |
| Jan 03, 2023 | Needham | $58.00 | $47.95 | 20.96% | -32.49% | |
| Dec 16, 2022 | Leerink Partners | $60.00 | $45.48 | 31.93% | -30.16% | |
| Dec 15, 2022 | Guggenheim | $66.00 | $45.72 | 44.36% | -23.18% | |
| Nov 17, 2022 | BTIG | $69.00 | $43.35 | 59.17% | -19.69% |
The latest Vaxcyte stock forecast, released on Nov 06, 2024 by Roger Song from Jefferies, set a price target of $146.00, which represents a 36.79% increase from the stock price at the time of the forecast ($106.73), and a 69.94% increase from PCVX last price ($85.92).
Vaxcyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 9 |
| Avg Price Target | - | $140.50 | $137.44 |
| Last Closing Price | $85.92 | $85.92 | $85.92 |
| Upside/Downside | -100.00% | 63.53% | 59.97% |
In the current month, the average price target of Vaxcyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vaxcyte's last price of $85.92. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 06, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Sep 04, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 03, 2024 | Needham | Buy | Buy | Hold |
| Sep 03, 2024 | BTIG | Buy | Buy | Hold |
| Sep 03, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 07, 2024 | BTIG | Buy | Buy | Hold |
| Mar 12, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Mar 12, 2024 | Wedbush | Buy | Buy | Hold |
| Jan 03, 2023 | Needham | Buy | Buy | Hold |
| Dec 16, 2022 | SVB Leerink | Outperform | Initialise | |
| Dec 15, 2022 | Guggenheim | Buy | Initialise | |
| Nov 17, 2022 | BTIG | Buy | Initialise | |
| Apr 26, 2022 | Needham | Buy | Buy | Hold |
Vaxcyte's last stock rating was published by Leerink Partners on Nov 06, 2024. The company gave PCVX a "Outperform" rating, the same as its previous rate.
Vaxcyte Financial Forecast
Vaxcyte Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $166.67K |
| High Forecast | - | - | - | - | - | - | - | $166.67K |
| Low Forecast | - | - | - | - | - | - | - | $166.67K |
| # Analysts | - | - | - | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Vaxcyte's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PCVX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vaxcyte EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| EBITDA | - | - | - | - | - | - | - | $-19.96M |
| Avg Forecast | - | - | - | - | - | - | - | $-12.81M |
| High Forecast | - | - | - | - | - | - | - | $-10.24M |
| Low Forecast | - | - | - | - | - | - | - | $-15.37M |
| Surprise % | - | - | - | - | - | - | - | 1.56% |
undefined analysts predict PCVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vaxcyte's previous annual EBITDA (undefined) of $NaN.
Vaxcyte Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| Net Income | - | - | - | - | - | - | - | $-20.32M |
| Avg Forecast | $-141.63M | $-137.92M | $-134.21M | $-133.59M | $-138.67M | $-136.16M | $-114.39M | $-13.12M |
| High Forecast | $-141.63M | $-137.92M | $-134.21M | $-133.59M | $-95.60M | $-136.16M | $-114.39M | $-10.50M |
| Low Forecast | $-141.63M | $-137.92M | $-134.21M | $-133.59M | $-227.97M | $-136.16M | $-114.39M | $-15.74M |
| Surprise % | - | - | - | - | - | - | - | 1.55% |
Vaxcyte's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PCVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vaxcyte SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| SG&A | - | - | - | - | - | - | - | $2.01M |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Vaxcyte's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PCVX last annual SG&A of $2.01M (Jun 20).
Vaxcyte EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 |
| EPS | - | - | - | - | - | - | - | $-1.72 |
| Avg Forecast | $-1.15 | $-1.11 | $-1.08 | $-1.08 | $-1.12 | $-1.10 | $-0.98 | $-1.27 |
| High Forecast | $-1.15 | $-1.11 | $-1.08 | $-1.08 | $-0.77 | $-1.10 | $-0.98 | $-1.27 |
| Low Forecast | $-1.15 | $-1.11 | $-1.08 | $-1.08 | $-1.84 | $-1.10 | $-0.98 | $-1.27 |
| Surprise % | - | - | - | - | - | - | - | 1.36% |
According to undefined Wall Street analysts, Vaxcyte's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PCVX previous annual EPS of $NaN (undefined).
Vaxcyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| STRO | Sutro Biopharma | $2.09 | $13.00 | 522.01% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| IMCR | Immunocore | $29.40 | $70.20 | 138.78% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| LQDA | Liquidia | $11.31 | $22.33 | 97.44% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| BMRN | BioMarin Pharmaceutical | $67.19 | $94.43 | 40.54% | Buy |
| ACLX | Arcellx | $82.03 | $111.60 | 36.05% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |
| TECH | Bio-Techne | $75.27 | $82.33 | 9.38% | Buy |
| VRDN | Viridian Therapeutics | $20.82 | $22.75 | 9.27% | Buy |